New drug combo tested to stop prostate cancer spread before surgery

NCT ID NCT01409200

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study tested whether adding the drug axitinib to standard hormone therapy before surgery helps men with prostate cancer that has spread to lymph nodes. About 73 men received either hormone therapy alone or hormone therapy plus axitinib before having their prostate removed. The goal was to see if the combination delays cancer recurrence after surgery.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
hormone therapy (androgen deprivation therapy) and axitinib
What this could lead to
If successful, this could point toward a more effective pre-surgery treatment for prostate cancer that has spread to lymph nodes.
What could go wrong
This is a small, early-phase trial (73 people) with no results yet. Adding axitinib may not improve outcomes and could increase side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC MALIGNANT NEOPLASM IN LYMPH NODE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.